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Abstract 
Background: Human, animal and cell experimental studies, human biomarker studies and genetic 
studies complement epidemiological findings and can offer insights into biological plausibility and 
pathways between exposure and disease but methods for synthesising such studies are lacking.  We 
therefore developed a methodology for identifying mechanisms and carrying out systematic reviews 
of mechanistic studies which underpin exposure-cancer associations. Methods:  A multidisciplinary 
team with expertise in informatics, statistics, epidemiology, systematic reviews, cancer biology and 
nutrition was assembled. Five one-day workshops were held to brainstorm ideas, in the intervening 
periods we carried-out searches and applied our methods to a case study to test our ideas. Results: 
We have developed a two stage framework, the first stage of which is designed to identify  
mechanisms underpinning a specific exposure-disease relationship , the second stage is atargeted 
systematic review of studies on a specific mechanism. As part of the methodology we also 
developed an online tool for text mining for mechanism prioritization (TeMMPo) and a new graph 
for displaying related but heterogeneous data from epidemiological studies (the albatross plot). 
Conclusions:  We have developed novel tools for identifying mechanisms and carrying out systematic 
reviews of mechanistic studies of exposure-disease relationships. In doing so we have outlined how we 
have overcome the challenges that we faced and provide researchers with practical guides for conducting 
mechanistic systematic reviews. Impact: The above methodology and tools will allow; potential 
mechanisms to be identified and the strength of the evidence underlying a particular mechanism to 
be assessed. 
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Introduction 
Systematic reviews offer robust methodology for identifying, appraising and synthesising studies 
that have addressed a common research question [1,2].  Such reviews are valuable in the synthesis 
of published literature relating to health care interventions, and to aetiological questions. However, 
reviews of observational epidemiological findings by themselves are insufficient to establish 
causation.  Other forms of evidence are required to complement such data in order to infer the likely 
causality of any observed association, in particular biological plausibility [3]. There is an abundance 
of evidence relating to the biology underpinning the causation of disease, from studies such as 
human, animal and cell experimental studies, human biomarker studies and genetic association 
studies, although methods have not been developed to synthesise this in a systematic way. 
Consequently, whilst epidemiological studies addressing chronic disease can be synthesised using a 
systematic process, mechanistic studies have previously been addressed using a results narrative.   
The World Cancer Research Fund and American Institute for Cancer Research have published a 
landmark report addressing the prevention of cancer through diet, nutrition and physical activity [4]. 
As part of the Continuous Update of the 2007 Report [5] WCRF UK commissioned the University of 
Bristol to develop a framework for reviewing mechanistic studies of exposures and cancer to test the 
likely causality of the observed associations. The aims were to: i) identify mechanistic studies that 
provide evidence of the biological plausibility of the causality of links between a diet, nutrition or 
physical activity exposure, and cancer; and ii) systematically review and assess the strength of the 
evidence for any one particular mechanism.  
Challenges in conducting systematic reviews of the mechanisms mediating observed associations 
between potentially modifiable exposures and cancer  
How to identify the relevant mechanisms for a particular exposure-outcome association?  
How to cope with the enormous wealth of data generated in searching for mechanisms?  
How to assess the quality of animal and cell studies?  
How to determine the relevance of animal studies to human disease?  
How to assess the extent of publication bias? 
How best to integrate all the evidence? 
We outline how we addressed the challenges inherent in developing an overall methodology 
outlined above.  A schematic diagram of the steps is given in Figure 1 with full details of the 
methodology presented in the Supplementary material.  
Materials and Methods: 
We approached colleagues and collaborators from the University of Bristol, University of Cambridge 
and the International Agency for Research on Cancer to assemble a multidisciplinary team with 
expertise in bioinformatics (TG), statistics (JHi, SH, KN, RM), cancer biology (JHo, CP, ST), animal 
studies (JHo, MG, ST), molecular biology (TG, JHo, CP, VT, ST), epidemiology (SL, PE, MJ, KN, RM), 
genetic epidemiology (SL, TG), nutrition (SR, PE, KN) and systematic reviews (SL, MG, JHi, RM). Our 
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objective to develop a rigorous systematic review methodology integrating animal, cell and human 
studies was met through a combination of discussion workshops and advice from a panel of experts. 
Decisions were reached by discussion and consensus opinion and then tested in practice. Results 
were fed back to the team and changes were made to the methodology if needed.   
We tested the framework by implementation in a case study examining the IGF pathway to 
determine whether this could explain observed associations between consumption of milk and 
incidence of prostate cancer (reported in full separately). To do this we systematically reviewed 
evidence on milk-intake and the IGF pathway, and between the IGF pathway and prostate cancer.[6] 
In this review we pooled together evidence from randomized controlled trials and other 
experimental studies in humans, observational, human biomarker, genetic and animal studies.  The 
feasibility and reproducibility of our methodology has been independently tested by two teams of 
systematic reviewers who initially searched for mechanisms between higher body fatness and 
postmenopausal breast cancer, and systematically reviewed the insulin-like growth factor 1 receptor 
as a potential mechanism for this association.[7]  The findings by Ertaylan et al  are published as an 
article in the same issue of this Journal. [7] 
Results: 
Identifying the relevant mechanisms for a particular exposure-outcome association 
We  have developed a two-stage strategy,  in stage 1 all potential mechanisms underlying a 
particular exposure-outcome association are identified, taking a largely ‘hypothesis-free’ approach, 
in stage 2 the evidence underlying one or more specific mechanisms are systematically reviewed. 
Fundamental to our approach are ‘intermediate phenotypes’ (IPs) between the exposure and 
disease (e.g. measures of DNA damage) as mechanistic studies frequently have an IP rather than 
cancer as an outcome, or will investigate the IP as the exposure in relation to an outcome. Stage 1 
assembles the evidence around IPs, to determine which have evidence linking them either to the 
exposure or to the outcome, and to quantify this evidence. For the study of milk and prostate cancer 
a list of potential IPs was generated (Table 1). In doing this we considered the biological processes 
that may lead to prostate cancer, referring to important reviews in the area of cancer such as those 
on the hallmarks of cancer, [8] which have been proposed as a framework for considering disordered 
biology in malignancies. In addition, reviews specific to the cancer site (in our case prostate cancer) 
were consulted to identify potential mechanisms. General MeSH terms relating to potential IPs were 
used in the search whenever possible, rather than more specific terms, as this allowed a broader 
search to be carried-out. Reviewers can generate their own list of IPs by listing terms relating to 
general cancer processes (such as the hallmarks of cancer), searching for reviews on the biology of 
their cancer site of interest and seeking expert opinion. We would advocate being as inclusive as 
possible at this point.  
Coping with the enormous wealth of data which is generated in searching for mechanisms 
The sheer number of papers generated in stage 1 (>39,000 in our case study of milk and prostate 
cancer) meant that we needed an efficient strategy for processing these data and prioritizing 
mechanisms for full systematic review in stage 2. Therefore, we have devised an automated process 
(‘Text Mining for Mechanism Prioritisation’, TeMMPo) which allows quantification and visualisation 
of the amount of evidence underlying each step in the mechanistic pathway (E → IP, IP → C, E → C, 
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where E is exposure, IP is intermediate phenotype and C is Cancer). This tool can be accessed at 
https://www.temmpo.org.uk/. The programme allows users to upload the results of their MEDLINE 
or PubMed searches, which are then displayed according to the intermediate phenotypes in a 
Sankey plot. This illustrates the quantity of evidence linking specific IPs with exposures (E → IP) and 
the quantity of evidence linking the same IPs with disease (IP → C); the relative number of 
publications underlying each link is depicted by the thickness of the lines linking the terms. A 
weighted score is generated as follows, the number of publications for E-IP or IP-C (whichever is the 
least) divided by the number of publications for E-IP or IP-C (whichever is the greater) multiplied by 
the total number of publications for each intermediate phenotype. According to this score IPs are 
then ranked.   These data then inform the selection of specific intermediates to be investigated in 
Stage 2.  Figure 2 shows a Sankey plot generated by TeMMPo indicating the quantity of studies 
linking milk with an IP and the quantity of studies linking the same IP with a prostate cancer 
outcome.  
The limitations of this approach are: it assumes that the co-occurrence of a biological mechanism 
with exposure or outcome in the literature represents an association rather than simply a co-
occurrence of the two terms in the same paper; it assumes the mechanisms are represented by a 
single mediating factor; recently identified pathways will be underrepresented in this approach as 
they are likely to have fewer studies; and it does not address issues of study type, quality, direction 
and magnitude of results.  
Systematically reviewing the evidence for a particular mechanism including assessing study quality 
Having identified potential mechanisms underlying a particular exposure-outcome association, stage 
2 systematically reviews the evidence underlying one or more specific mechanisms. For our study of 
milk-prostate cancer, we chose to systematically review the IGF pathway, since our stage 1 searches 
indicated that on combining all related IP terms , there were more studies linking IGF intermediates 
(i.e. a combination of IGF-I, IGF-II, IGF-IR, IGFBP3, IGFBP1) with both milk and prostate cancer than 
for other potential mechanisms.  
Stage 2 largely follows standard systematic review methodology (see Appendix 1): specification of 
research objectives; conduct searches (see Supplementary table 1 as a guide for developing search 
terms); apply inclusion/exclusion criteria; extract data; assess study quality and synthesise data 
across studies. Existing tools for assessing study quality have not been validated or established for 
mechanistic [9-11] nor animal studies [12]. We recommend the Cochrane risk of bias tools for 
human studies [9] and SYRCLE (Systematic Review Centre for Laboratory animal 
Experimentation)[13], which adapts the Cochrane tool[9], for aspects of bias that are specific to 
animal studies. SYRCLE addresses the following domains:  
• Bias due to confounding (sequence generation, baseline characteristics, allocation 
concealment) 
• Bias due to departures from intended intervention (e.g. due to lack of random housing of 
animals or lack of blinding) 
• Bias due to missing data 
• Bias in measurement of outcomes 
• Bias in selection of reported results 
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As far as we are aware there are currently no tools for assessing the quality of cell line studies so we 
developed the criteria listed in Box 3 through consensus of the Framework development group 
which included cell biologists. Supplementary table 2 recommends variables to extract by study type 
at data extraction stage in order to complete the risk of bias assessments.   
Criteria used for assessing the quality of cell studies 
• 1) Have the cells been obtained from a validated repository that guarantees cell 
verification or have the cells been appropriately independently verified?2) ) Have sufficient 
biological and technical repeats of the experiments been conducted and were appropriate 
controls included? 
• 3) Were different cell lines from the same cancer type used in the study? An effect 
observed in more than just one cell line implies the effect is important and relevant to this 
cancer type. 
• 4) Are culture conditions comparable between different studies? 
• 5) Selective reporting: are only selected results from several cell line experiments 
reported? 
• 6) Were cell lines from different cancer types compared? This implies an important effect 
that is relevant more generally to cancer cells. 
 
We recommend that questions 1-3 above are used to determine inclusion of cell studies into the 
review. In our study of milk-IGF-prostate cancer only a small proportion of relevant cell studies met 
this basic quality criteria (Figure 3). However, it is a recent requirement to provide authentication of 
cell lines and other quality control criteria for publication. Thus in applying these criteria we are 
selecting more recent studies and may be excluding high quality historical studies which were not 
required to provide information on the above in order to publish. Questions 4-6 can be used to assess 
the reproducibility of the findings from cell studies.  
Synthesis of individual studies and ‘albatross plots’ for graphical representation of evidence 
synthesis, when meta-analysis is not appropriate  
The next step is the synthesis of data from individual studies. Formal meta-analysis of comparable 
studies is recommended where possible and appropriate [14]. However, it is likely that mechanistic 
studies will be too heterogeneous (in terms of exposure and outcome definitions; different follow-
up periods; different study types) to combine, and therefore some studies will only be amenable to a 
narrative summary of the results. We therefore developed a new method to graphically represent 
heterogeneous data, which we have termed ‘albatross plots’ [15]. These plots allow for the strength 
and direction of association to be displayed continuously, plotting p-values against the number of 
participants in the studies (which will give an indication of the relative power of the study) (Figure 4). 
Clustering of data points towards one side of the graph represents an association between exposure 
and outcome in that direction. In Figure 4 the majority of studies are on the right side of the graph 
indicating a positive association of exposure (milk and dairy products) with outcome (IGF-I). Small 
studies will only have low p-values if the effect size is large, whereas large studies may have low p-
values even when the effect size is small. 
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Contour lines which indicate a specific beta-coefficient can be added to the plot to indicate (to some 
extent) the magnitude of association. Simple contours can be computed based on p-values and the 
number of participants, although it should be noted that such contours are not sufficient or 
appropriate to provide a precise effect estimate (as a forest plot would). Contours can be added if 
the majority of data have been analysed in the same way (linear or logistic regression, or 
standardised mean differences), and the contour will be of the same type of effect estimate (e.g. a 
standardised beta coefficient for linear regression). If data points fall along a contour (which is 
shaped like a bird’s wing, hence ‘albatross plots’) then there is likely to be an association of the 
magnitude represented by the contour; however, this needs to be interpreted with a narrative and 
consideration of the individual studies in the synthesis. 
We did not find any animal or cell studies which addressed the association between milk and IGF 
intermediates, but the 8 animal studies on IGF-prostate cancer outcomes were too varied (different 
experiments, on alternative aspects of the IGF pathway, in diverse animal models, with varied 
outcomes), to combine in a plot. Characteristics and results of these studies were tabulated (see 
reference [6]). A schematic diagram of the likely biological pathway generated from animal and cell 
line studies is another way of presenting the data. 
Assessment of the strength of evidence and classification of studies according to relevance to 
humans 
Once the synthesis of evidence has been completed, the framework requires an assessment of the 
strength of the body of evidence. We recommend doing this separately for human and animal 
studies, according to the GRADE framework [16], which has been adopted by the Cochrane 
Collaboration.  
Whilst our remit was to design a framework which could be used to incorporate relevant evidence 
from any type of study, some studies were so far removed from humans that they could not inform 
a judgement that a particular process is operating in the human disease pathway. However, such 
studies could be used to assess general biological plausibility. For cancer we chose to distinguish 
between two types of animal models by applying the question “Has the cancer arisen de novo in the 
animal model rather than being transplanted into the animal?” This is because transplantable 
models represent cancers that are already highly evolved as they have adapted growth in vitro (in 
the case of cell line xenografts) or in vivo growth in patient-derived xenograft models (human 
tumour cells taken from host patient and transplanted into immunodeficient mice), and are typically 
of a more aggressive biological phenotype; as such they do not closely mimic most human cancers 
and are unlikely to give useful information about the usual process of cancer development or 
progression.  
We recommend that only studies that closely mimic human cancers should be used to determine 
the strength of the evidence underlying a particular mechanistic pathway in human cancer. Other 
animal studies could be assessed alongside cell line studies to determine whether they provide 
evidence for the general biological plausibility of the proposed mechanism.  
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In addition to this two-tiered distinction when applying the GRADE framework, studies are assessed 
according to the following criteria: indirectness (this relates to the how well the study addresses the 
specific research question), inconsistency, imprecision and publication bias. 
As we are not aware of the GRADE framework being previously applied to animal studies, the 
question of indirectness in particular required some consideration. We therefore developed some 
questions to assess this specifically for animal studies. 
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Assessing the indirectness of animal studies when applying the GRADE framework 
• Is the exposure applied via a route which is comparable with that in humans, and a mode 
which addresses the research question? (e.g. If the interest is in a food exposure, then this 
should be ingested by the animal model, for other exposures it may be appropriate to 
introduce this via an alternative route) 
• Is the level and frequency of exposure comparable with that which humans may 
experience after accounting for species differences in pharmacokinetics and 
pharmacodynamics, or is the dose justified within the study? (much greater doses than 
would be possible or reasonable in humans are unlikely to reflect human exposures) 
• Is the cancer induced (i.e. by a virus, radiation, chemical agent or genetic manipulation)? 
(whether or not these studies can be included will depend on the research question, but the 
agent used should be relevant to the human cancer)   
• Is the time at which the outcome is assessed justified? Whether the timing of outcome 
assessment is relevant will depend on the outcome; e.g. if the outcome is a gene mutation 
then that outcome could justifiably be assessed very quickly following exposure, but if the 
outcome is cancer this may require much longer follow-up to produce relevant data.  
• Does the study explore mechanisms or pathways of cancer development? 
• Is the outcome of assessment cancer incidence or progression rather than surrogate 
measures of tumour activity such as tumour size or number of tumours? 
• Do the outcome measures mimic those found in humans? More specifically, does the 
tumour mimic the human disease in terms of the organ or tissue affected, and at the 
histopathological (tissue patterns, or cell surface or intracellular protein expression levels) 
or genetic level (are equivalent hallmark genetic lesions observed as well as gene 
expression profiles). Does the progression of the disease mimic the human cancer (e.g. 
metastasis to the same sites, vascular and stromal invasion, response to treatment)?  
If the answer to one or more of these questions is no, then the individual study should be considered 
to offer indirect evidence; if the majority of studies in the body of evidence are considered to offer 
only indirect evidence then the overall GRADE assessment across these studies should be 
downgraded.  For example we downgraded animal studies of IGF and prostate cancer because 
knock-out mice do not represent variation within the normal range and in some studies the outcome 
measured was tumour weight or volume rather than incidence. 
Investigating whether publication bias is likely to have occurred 
There is empirical evidence that studies with null results (no association) are less likely to be in the 
published literature. Null studies may also be affected by “time lag bias” or longer time to 
publication. Funnel plots and the Begg  [17] and Egger  [18] tests can be used to examine for 
association between effect sizes and study sizes (essentially sample size), and such an association 
(‘small study effect‘) may reflect publication bias. However, these approaches may not be possible 
due to an insufficient number of similar studies with the same exposures and outcomes measured.  
Ioannidis and Trikalinos [19] have developed a method to test for excess statistical significance 
across studies on different research questions within the same domain.  Domains may be defined 
according to a common general theme, intervention type, subject type, methodology, research 
environments and language of publication or combinations of these factors. The test is a comparison 
of the number of observed studies with statistically significant results compared against the number 
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of expected statistically significant results amongst all meta-analyses considered in the domain. This 
test can be applied to assess publication bias across domains.  
An alternative approach is to qualitatively assess publication bias by obtaining data on unpublished 
studies (e.g. by searching the grey literature and/or contacting researchers working in the field) to 
determine whether relevant unpublished experiments or observational studies have been carried 
out. It is difficult to be systematic about such investigations, but attempts should be fully reported to 
ensure transparency of the process. Reviewers can then compare the results of any unpublished or 
grey literature studies with those which have been published to determine if there are important 
differences in the results.  This process may indicate non-, delayed or restricted (e.g. in difficult to 
retrieve journals) publication of null data, suggesting distortion of the mainstream literature by 
publication bias.   
Assessing the strength of evidence across evidence streams and synthesis of cell line and other 
animal studies  
In the WCRF International/University of Bristol framework (Supplementary material), we have set 
out a model for assessing the totality of evidence by determining the strength of the overall 
evidence from human and animal studies which reflect the human disease process (see figure 5).  In 
addition, we advocate using other studies to illustrate biological plausibility and illustrate the 
potential intricacies of the biological pathway.  
Discussion: 
We have developed methodology which can be used to identify potential mechanisms underlying 
observed associations between an exposure and an outcome and to systematically review a 
mechanistic pathway of interest. We have overcome several hurdles including: developing an 
automated online tool (https://www.temmpo.org.uk/) to deal with the vast amounts of studies 
identified in stage 1; recommending tools for assessing the quality and relevance of animal and cell 
studies to human disease; and developing a new method for synthesising data from a variety of 
study types, the albatross plot. However, implementing the methodology does have some 
limitations, the main one being that it is very time consuming which may constrain its use. In 
addition, we have seen from our case study that many animal and cell studies do not report basic 
information that we recommend using to assess their quality, this is particularly true for older 
research findings. This means that many studies which are pertinent to the research question may 
not be included in the overall analysis.  Furthermore there is a question mark over the relevance of 
animal experiments to the human situation, although we have made suggestions for assessing how 
relevant they may be and for weighting these studies accordingly in the overall analysis.   
We believe that the methodology we have developed can be applied to the integration of 
mechanistic studies into systematic reviews of exposures and disease in order to aid the inference of 
causality, and in addition may highlight gaps in our knowledge where further studies are needed. 
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MESH Terms (in bold) and more specific terms (non-bold) Receptors, Steroid 
Nerve Growth Factors Bone Marrow 
Brain-Derived Neurotrophic Factor Enterochromaffin Cells 
Ciliary Neurotrophic Factor Immunological Synapses 
Glia Maturation Factor Leukocytes 
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Glial Cell Line-Derived Neurotrophic Factors Lymphatic System 
Nerve Growth Factor Mast Cells 
Neuregulins Phagocytes 
Neurotrophin 3 Mononuclear Phagocyte System 
Pituitary Adenylate Cyclase-Activating Polypeptide  Angiogenesis Modulating Agents 
Membrane Transport Proteins Angiogenesis Inducing Agents 
ATP-Binding Cassette Transporters Angiogenesis Inhibitors 
Amino Acid Transport Systems Signal Transduction 
Fatty Acid Transport Proteins Ion Channel Gating 
Ion Channels Light Signal Transduction 
Ion Pumps MAP Kinase Signaling System 
Monosaccharide Transport Proteins Mechanotransduction, Cellular 
Neurotransmitter Transport Proteins Second Messenger Systems 
Nucleobase, Nucleoside, Nucleotide, and Nucleic Acid Transport 
Proteins Synaptic Transmission 
Nucleocytoplasmic Transport Proteins Energy Metabolism 
Racemases and Epimerases Basal Metabolism 
Amino Acid Isomerases- Alanine Racemase Citric Acid Cycle 
Carbohydrate Epimerases- UDPglucose 4-Epimerase Glycolysis 
Glutathione Transferase Oxidation-Reduction 
Glutathione S-Transferase pi Oxidative Phosphorylation 
Androgens Pentose Phosphate Pathway 
Dihydrotestosterone Photophosphorylation 
Nandrolone Proton-Motive Force 
Oxandrolone Substrate Cycling 
Oxymetholone Cell Differentiation 
Stanozolol Adipogenesis 
Testosterone Asymmetric Cell Division 
Androgen Antagonists Embryonic Induction 
Chlormadinone Acetate Gametogenesis 
Cyproterone Hematopoiesis 
Cyproterone Acetate Neurogenesis 
Flutamide Cell Death 
Trans Activators Apoptosis 
Gene Products, tat Autophagy 
Herpes Simplex Virus Protein Vmw65 Necrosis 
  
 
 
Very Broad/General MESH terms not sub-divided for more 
specific terms  
 
Receptors, Androgen  
Receptors, Estrogen Molecular Mechanisms 
Receptors, Glucocorticoid Physiology 
Receptors, Mineralocorticoid Cell Physiological Processes  
Receptors, Progesterone MESH terms without more specific terms 
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Genomic Instability Selenium 
Chromosomal Instability- Chromosome Fragility MicroRNAs 
Microsatellite Instability DNA methylation 
DNA Damage C-Reactive Protein 
DNA Adducts Telomerase 
DNA Breaks- Chromosome Breakage  
DNA Degradation, Necrotic 
Hormones and Growth Factors (Title- not MESH 
term) 
DNA Fragmentation Testosterone 
DNA Repair Estrogens 
DNA End-Joining Repair Somatomedins 
DNA Mismatch Repair Insulin-Like Growth Factor I 
Recombinational DNA Repair Insulin-Like Growth Factor II  
SOS Response Insulin-Like Growth Factor Binding Proteins 
Gene Expression Insulin-Like Growth Factor Binding Protein 1 
Protein Biosynthesis Insulin-Like Growth Factor Binding Protein 2 
Transcription, Genetic- Reverse Transcription; Transcriptome Insulin-Like Growth Factor Binding Protein 3 
Mutation Insulin-Like Growth Factor Binding Protein 4 
Allelic Imbalance Insulin-Like Growth Factor Binding Protein 5 
Base Pair Mismatch Insulin-Like Growth Factor Binding Protein 6 
Chromosome Aberrations  
Codon, Nonsense Vitamins and Minerals (Title- not MESH term) 
DNA Repeat Expansion Calcium, Dietary 
Frameshift Mutation Vitamin D 
Gene Amplification 
 
Mutagenesis 
Gene Duplication Amino Acid SubstitutionSequence Inversion  
Germ-Line Mutation Chromosome Duplication 
INDEL Mutation Nondisjunction, Genetic 
Mutagenesis, Insertional Somatic Hypermutation, Immunoglobulin 
Mutation Rate Translocation, Genetic 
Mutation, Missense Genomic Instability 
Point Mutation Chromosomal Instability- Chromosome Fragility 
Sequence Deletion Suppression, Genetic  
 Microsatellite Instability 
  
  
Cytokines 
Terms entered as Title not MESH terms 
 
Inflammation  
Chemokines Immunity  
Growth Differentiation Factor 15 Programmed Cell Death  
Hematopoietic Cell Growth Factors Physiology Programmed Cell Death  
Hepatocyte Growth Factor ProstatitisPhysiology  
Interferons Physiology Prostatitis 
Interleukin 1 Receptor Antagonist Protein ProstatitisPhysiology  
Interleukins Prostatitis 
15 
 
Leukemia Inhibitory Factor  
Lymphokines  
Monokines  
Oncostatin M  
Osteopontin  
Transforming Growth Factor beta  
Tumor Necrosis Factors  
Cell Proliferation  
Cell Division- Asymmetric Cell Division; Telomere Homeostasis  
Immune System  
Antibody-Producing Cells  
Antigen-Presenting Cells  
  
Table 1: Intermediate phenotypes used in a review of milk and prostate cancer 
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Figure legends: 
Figure 1: Steps for stage 2 
Figure 1 shows an outline of the steps we recommend going through in stage 2 of our methodology 
to review the evidence for a specific mechanism. 
Figure 2: A Sankey plot of milk-IGF-prostate cancer 
Figure 2  shows a Sankey plot which indicates visually the quantity of evidence linking exposure to 
different intermediate phenotypes and the quantity of evidence linking the same intermediate 
phenotypes to outcome. This particular Sankey plot shows the quantity of evidence for milk and IGF 
on the left hand side and the quantity of evidence for IGF-prostate cancer on the right hand side of 
the plot. 
Figure 3: Pie chart showing proportion of cell studies included after applying quality control criteria 
and reasons for exclusion in our study of milk-IGF-prostate cancer.   
Figure 3 shows that our  search identified 74 papers of cell studies relevant to milk-IGF-prostate 
cancer the research question; of these, 59 were excluded because they did not use authenticated 
cell lines (n=28); carried out experiments in only one authenticated cell line (n=26); or did not 
validate results in more than 3 repeat experiments (n=5).  
Figure 4: Albatross plot of milk, dairy products and dairy proteins (exposures) and IGF-I (outcome).  
Figure 4 shows that the majority of studies are on the right side of the graph, indicating a positive 
association of exposure with outcome. Note also that the majority of studies showing an association 
do so around a standardised beta coefficient (Beta) of 0.1, which is a 0.1 standard deviation increase 
in outcome for a 1 standard deviation increase in exposure.  
Figure 5: A guide to integrating the evidence from human and animal studies to reach an overall 
conclusion on the strength of evidence for a particular mechanism underlying an exposure and 
cancer association  
Figure 5 shows how overall conclusion on the strength of evidence for exposure –intermediate and 
intermediate-outcome may be reached based on evidence from animal and human studies. This was 
adapted from the National Toxicology Program)[20]  
 
 
 
 
  
 
